cemacabtagene ansegedleucel
Cell therapy
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Company guidance: interim data expected mid-2027 (NCT06500273; Allogene Therapeutics, Inc., 6 Nov 2026). “We currently anticipate that a planned interim EFS analysis for ALPHA3 will occur in mid-2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04416984 NCT04416984 · Large B-Cell Lymphoma Registry: NCT04416984 | 1/2 | Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicities (DLT) at increasing doses of ALLO-501A (28 days); Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-501A (33 days); Phase 1b: Frequency and severity of ALLO-501A treatment-emergent adverse events (AEs), serious AEs, and AEs of special interest (Up to 60 months); Phase 2: Overall Response Rate (ORR) assessed per Independent Review Committee (IRC) (Up to 60 months) 2029-02 | In progress: results expected 1 Feb 2029 | not yet graded | link ↗ |
View 1 more trial
ALPHA3 NCT06500273 · Large B-Cell Lymphoma Registry: NCT06500273 | 2 | Event-free survival per independent review committee assessment (Up to 60 months) 2027-12 | In progress: results expected 1 Dec 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other CD19 drugs
Inebilizumab, obecabtagene autoleucel, Tafasitamab, budoprutug, FT819 and 11 more. Compare all 17 CD19 drugs
This mechanism is crowded: 18 other tracked programmes target it, 3 of them ahead of this one.
This drug's own stage for Large B-Cell Lymphoma: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cemacabtagene Ansegedleucel: this drug | Phase 2 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Brentuximab Vedotin | Approved | Antibody–drug conjugate | Anti-CD30 antibody-drug conjugate | not yet graded | No reviewed efficacy summary in this indication | |
| Epcoritamab | Approved | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Inebilizumab | Approved(overall) | Monoclonal antibody | CD19 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Obecabtagene Autoleucel (Aucatzyl) | Approved(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved | Monoclonal antibody | CD19 | Weak signal | NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants | |
| Golcadomide | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Rondecabtagene Autoleucel | Phase 3 | Cell therapy | CD19 / CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 3 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Budoprutug | Phase 2(overall) | Monoclonal antibody | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| FT819 | Phase 2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Rapcabtagene Autoleucel | Phase 2(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Beijing Biotech Anti-CD19 CAR-T | Phase 1/2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zugocabtagene Geleucel | Phase 1/2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-319 | Phase 1(overall) | Antibody–drug conjugate | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-519 | Phase 1(overall) | — | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Azercabtagene Zapreleucel | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| IC19 CAR-T | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| UTAA09 | Phase 1(overall) | Cell therapy | CD19 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| ZM001 | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-619 | —(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| FT522 | —(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| GLPG5101 | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Vispacabtagene Regedleucel | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow cemacabtagene ansegedleucel to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
Company guidance: interim data expected mid-2027 (Allogene Therapeutics, Inc., 6 Nov 2026). “We currently anticipate that a planned interim EFS analysis for ALPHA3 will occur in mid-2027.” Source ↗